替格瑞洛用于经颈动脉血运重建术患者的个体化抗血小板治疗结局与策略
研究还提出了基于血小板反应性检测的替格瑞洛给药方案。
要点
- TCAR围术期使用替格瑞洛联合阿司匹林双联抗血小板治疗未发生30天大出血事件。
- 30天内无同侧脑血管缺血事件、心肌梗死或死亡发生。
- 替格瑞洛可能作为氯吡格雷无反应者的安全有效替代方案。
核心结论
- 替格瑞洛作为TCAR患者双联抗血小板治疗的一部分,在症状性和无症状性颈动脉狭窄中均显示出安全性和有效性。
- 未发生出血事件或血栓栓塞并发症,替格瑞洛可能是克服氯吡格雷无反应性的安全有效替代方案。
研究设计与样本
- 患者平均年龄79岁,28例(42%)为症状性。
- 术前采用血栓弹力图血小板图检测血小板反应性,以二磷酸腺苷诱导的最大振幅<50 mm定义为血小板反应性充足。
主要发现
- 平均手术时间45.8±9.2分钟,平均阻断/血流逆转时间4.8±1.5分钟。
- 住院患者平均术后住院时间3.1±2.2天,门诊患者1.3±0.8天。
- 所有病例均获得技术成功,30天内无大出血事件,无同侧脑血管缺血事件、心肌梗死或死亡。
关键数值与推荐
- 主要安全终点为30天主要出血事件率,主要疗效终点为30天同侧脑血管缺血事件(卒中或短暂性脑缺血发作)、心肌梗死和死亡发生率。
- 术前血小板反应性采用血栓弹力图血小板图检测,血小板反应性充足定义为二磷酸腺苷诱导的最大振幅<50 mm。
临床怎么用
- 对于接受TCAR的患者,可考虑使用替格瑞洛联合阿司匹林作为双联抗血小板治疗方案。
- 可通过血栓弹力图血小板图检测指导替格瑞洛的用药和患者管理,以确保围术期充分抗血栓保护。
局限性
- 回顾性研究设计。
- 单中心经验,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antiplatelet drug resistance is associated with periprocedural ischemic complications in patients undergoing intravascular stent implantation. Nonresponders are subject to increased risk of stent thrombosis and in-stent stenosis, and high on-treatment platelet reactivity (HTPR) is present in up to 44% of patients taking clopidogrel, a widely used component of dual antiplatelet therapy (DAPT). Evidence points to ticagrelor as a viable alternative to overcome HTPR on clopidogrel. Studies have shown fewer thromboembolic events with ticagrelor therapy; however, results on bleeding risk are mixed, and its safety and efficacy in hybrid operative techniques have yet to be established. Transcarotid artery revascularization (TCAR) is a hybrid procedure to treat severe carotid stenosis. The objective of this study was to establish the safety and efficacy of ticagrelor as part of DAPT in patients undergoing TCAR and to develop a protocol to ensure adequate antithrombotic protection throughout the operative course. METHODS: Data were collected retrospectively for patients undergoing TCAR on DAPT of aspirin and ticagrelor for symptomatic (≥50%) or asymptomatic (≥80%) carotid stenosis. Preoperative platelet reactivity was determined using Thromboelastography with Platelet Mapping (Haemonetics Corporation, Braintree, Mass), with adequate platelet reactivity defined as maximal amplitude produced by adenosine diphosphate <50 mm. The primary safety end point was 30-day major bleeding event rate. Primary efficacy end points were 30-day incidence of ipsilateral cerebrovascular ischemic event (stroke or transient ischemic attack), myocardial infarction, and death. Secondary end points were postoperative length of hospital stay, procedure time, and clamp/flow reversal time. RESULTS: Sixty-seven TCAR procedures with patients receiving periprocedural DAPT of ticagrelor and aspirin were performed during the study period. Patients had an average age of 79 years, and 28 (42%) were symptomatic. The mean procedure time was 45.8 ± 9.2 minutes, with a mean clamp/flow reversal time of 4.8 ± 1.5 minutes, and mean postoperative length of hospital stay of 3.1 ± 2.2 days for inpatients and 1.3 ± 0.8 days for outpatients. Technical success was achieved in all cases, with no 30-day major bleeding events and no occurrence of ipsilateral cerebrovascular ischemic event, myocardial infarction, or death. CONCLUSIONS: Initial experience with ticagrelor as part of DAPT in patients undergoing TCAR demonstrated its safety and efficacy in both symptomatic and asymptomatic disease. No bleeding events or thromboembolic complications occurred. Furthermore, a protocol to administer ticagrelor to assay for HTPR on ticagrelor and consequent medication and patient management is proposed. Ticagrelor may represent a safe and effective alternative to overcome clopidogrel nonresponsiveness in DAPT regimens for TCAR.
引用
- Ghamraoui AK, Ricotta JJ. Outcomes and strategy of tailored antiplatelet therapy with ticagrelor in patients undergoing transcarotid artery revascularization. J Vasc Surg. 2020. PMID: 32445834. doi:10.1016/j.jvs.2020.04.518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。